UBS Group
DSGN icon

UBS Group’s Design Therapeutics DSGN Stock Holding History

UBS Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Buy
34,761
+17,670
+103% +$220K ﹤0.01% 6226
2026
Q1 		$182K Sell
17,091
-8,446
-33% -$85.5K ﹤0.01% 6688
2025
Q4 		$240K Buy
25,537
+2,844
+13% +$22.3K ﹤0.01% 6483
2025
Q3 		$171K Sell
22,693
-4,649
-17% -$23.3K ﹤0.01% 6765
2025
Q2 		$92.1K Sell
27,342
-5,477
-17% -$20.5K ﹤0.01% 7308
2025
Q1 		$127K Sell
32,819
-33,768
-51% -$161K ﹤0.01% 6863
2024
Q4 		$411K Buy
66,587
+51,707
+347% +$299K ﹤0.01% 5983
2024
Q3 		$80.1K Buy
14,880
+1,520
+11% +$7.15K ﹤0.01% 6508
2024
Q2 		$44.8K Sell
13,360
-19,673
-60% -$76.7K ﹤0.01% 6774
2024
Q1 		$133K Sell
33,033
-17,408
-35% -$46.5K ﹤0.01% 6091
2023
Q4 		$134K Buy
50,441
+32,377
+179% +$74.2K ﹤0.01% 6021
2023
Q3 		$42.6K Sell
18,064
-6,098
-25% -$28.4K ﹤0.01% 6395
2023
Q2 		$152K Buy
24,162
+23,956
+11,629% +$147K ﹤0.01% 5673
2023
Q1 		$1.19K Sell
206
-155,821
-100% -$1.17M ﹤0.01% 8785
2022
Q4 		$1.6M Buy
+156,027
New +$2.11M ﹤0.01% 3606
2022
Q2 		– Sell
-998
Closed -$16K – 10432
2022
Q1 		$16K Buy
998
+963
+2,751% +$14.8K ﹤0.01% 7732
2021
Q4 		$1K Sell
35
-1,099
-97% -$18.9K ﹤0.01% 9963
2021
Q3 		$17K Buy
1,134
+636
+128% +$10.6K ﹤0.01% 7328
2021
Q2 		$10K Buy
498
+198
+66% +$5K ﹤0.01% 8031
2021
Q1 		$9K Buy
+300
New +$10.1K ﹤0.01% 7997

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's DSGN Position: Q2 2026 in Review

UBS Group increased its Design Therapeutics (DSGN) stake by 103% in Q2 2026, buying an estimated $220K and bringing the position to 34,761 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #6226.

UBS Group first reported a position in DSGN in Q1 2021 and has held it in 20 quarters since. The position peaked at $1.6M in Q4 2022. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • UBS Group held 34,761 shares of Design Therapeutics worth $503K as of Q2 2026.
  • UBS Group bought 17,670 Design Therapeutics shares in Q2 2026, an estimated $220K.
  • Design Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6226 holding.
  • UBS Group first reported a position in Design Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • UBS Group's Design Therapeutics position peaked at $1.6M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.